Results 221 to 230 of about 176,622 (333)

Circulating hsa‐miR‐29c‐3p and VEGF‐A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

European Journal of Clinical Investigation, EarlyView.
Metastatic colorectal cancer (mCRC) patients who progress on oxaliplatin‐based chemotherapy benefit from second‐line treatment with FOLFIRI plus aflibercept. However, the absence of validated biomarkers for antiangiogenic therapies remains a challenge. Circulating levels of VEGF‐A and 13 miRNAs were analysed in 154 elderly mCRC patients.
Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Elena Élez, Javier Soto‐Alsar, David Páez, Ana Fernández‐Montes, Begoña Graña, Antonieta Salud, Alfonso Yubero, Ismael Macías, Guillermo Quintero, Carlos López‐López, Teresa Fernández‐Rodríguez, María Victoria García‐Ortiz, Javier Sastre, Pilar García‐Alfonso, Antonio Rodríguez‐Ariza, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)   +18 more
wiley   +1 more source

Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis. [PDF]

Ann Coloproctol
Su YC, Su CC, Lee PT, Wu CC.
europepmc   +1 more source

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial

Patrick Boland, Sarbajit Mukherjee, Iman Imanirad, Namrata Vijayvergia, Seth D. Cohen, Medhavi Gupta, Renuka Iyer, Andrei V. Bakin, Jianxin Wang, Sarah Chatley, Beth Cahill, Deepak Vadehra, Kristopher Attwood, Howard S. Höchster, Christos Fountzilas   +14 more
openalex   +2 more sources

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

The FEBS Journal, EarlyView.
Autophagy is a cellular degradation process involved in, for example, immune responses to pathogens and neurodegeneration. To identify modulators of autophagy, we developed a microscopy‐based screening assay and identified previously unknown autophagy‐modulating activities in known drugs and natural products from myxobacteria and fungi.
Janine Fichtner, Yan Yan Beer, H. G. Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Rolf Müller, Manfred Wirth, Eeva‐Liisa Eskelinen, Ingo Schmitz   +13 more
wiley   +1 more source

Genomics of ovarian cancers and the potential of precision medicine. [PDF]

Ther Adv Med Oncol
Jarratt A, Polidano J, Scott CL, Barker HE.   +3 more
europepmc   +1 more source

TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis

Youwen Zhu, Kun Liu, Hong Zhu
openalex   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Evaluation of gefitinib alone or combined with bevacizumab in patients with <i>EGFR</i> L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers. [PDF]

Transl Lung Cancer Res
Zhao X, Wu X, Wang H, Yu H, Sun S, Hu Z, Lin Y, Zhang Y, Yu B, Wu Z, Xiong K, Liu C, Wang S, Bao H, Ou Q, Wang J.   +15 more
europepmc   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source